CEO/CFO - Timothy L. Ramsey, MBA has an extensive background in both entrepreneurship and biotechnology. In addition to an advanced degree in biochemistry, he gained experience in creating financial models for early stage drugs and strategic plans for drug development as the CFO for Neuroscience Discovery at Eli Lilly. Previously, he is one of three individuals devoted full-time to strategy at Lilly Research Labs, a $3 B/yr R&D organization. Previously, he co-founded Iterative Therapeutics, a Chicago-based biotech start-up. He led a team that transformed Iterative from a laboratory project into a business that has earned STTR grants and has begun the fund raising process. Mr. Ramsey earned his MBA from the University of Chicago and his M.S. in biochemistry from the University Of Louisville School Of Medicine.


Chief Scientific Officer - Mark D. Brennan, Ph.D. is Cofounder and Manager of SureGene, and lead inventor of the AssureGene^TM test. He is a Professor in the Department of Biochemistry and Molecular Biology at the University of Louisville. Dr. Brennan is a Cofounder of the University of Louisville’s Center for Genetics and Molecular Medicine. His research has been supported by over $7 million in grant funding since 1985.  He is currently Principle Investigator of a Kentucky Science and Technology Corporation R & D Voucher Award and of an SBIR grant from the National Institutes of Mental Health for development of genetic biomarkers for neuropsychiatric illnesses.

VP Genetic Counseling - Holly Neibergs, Ph.D. is a co-inventor of the AssureGene^TM test. In addition to her participation in SureGene, she is Director of the Norton Hereditary Cancer Institute, President of Genetic Assesments, and an Adjunct Faculty member at the University of Louisville. She received her Bachelor and Master of Science degrees from Washington State University and her doctorate in genetics from Texas A&M University. She is certified in Familial Cancer Risk Asessment and Management and has been involved with genetic counseling for over 5 years. Her research interests have spanned a 20-year period and have focused on comparative genomics and genetically complex diseases.